The Puissant laboratory (https://thepuissantlab.jimdo.com/) is welcoming applications from post-doctoral candidates motivated to join an international ERC-sponsored research lab specialized on leukemia research.The position is available for three years, renewed each year.
Our laboratory deciphers molecular mechanisms
involved in leukemia development and chemoresistance
in pre-clinical mouse models of AML.
Unbiased in vivo screening approaches are deployed in order to provide new therapeutic strategies to treat AML. Large-scale shRNA screening, as well as genome-wide approaches(WES, RNA-Seq, ChIP-Seq), are currently used in this lab. Our ambitious project cover multidisciplinary approaches of cancer biology,molecular biology, cell biology, animal modeling and experimental therapeutics.
Our laboratory is located at the Saint-Louis Research Institute (INSERM U944) in Paris, France.
The research developed in this institute encompasses a broad spectrum of fields, including cancer genomics,cancer biology and leukemia research. Most studies carried out in the unit have implications in translational research, together with clinical groups of the Saint-Louis Hospital. Our laboratory benefits from a direct access to the core facilities including: a recently extended animal facility, a sequencing facility (Mi-seq, Hiseq, and Nextgen-seq technologies), and a flow core facility.
We are looking for a highly motivated candidate with extensive experience in molecular and cellular biology, and solid skills in working with engineered and patient-derived xenograft mouse models. Applicants should hold a PhD degree in Biochemistry/Molecular Biology or related disciplines (or have recently submitted their thesis with scheduled defense) and have published (or about to publish) in a peer reviewed journal.
Applicants with competencies in bioinformatics are welcome. Experience in epigenetics/epigenomics would be an asset.
Candidates are invited to contact Nina Fenouille (email@example.com) for further details,
before August 31st 2019.
Formal application should consist of the following (one single pdf file applicantName_application2019.pdf):
- Curriculum vitae, including publication list and contact details for 3 referees,
- Concise summary of previous research activities,
- Cover letter clearly indicating the applicant’s motivations.
Selected Publications on the topic:
Ben-Sahra I, Puissant A. HER2 Signaling Hijacks the Creatine Shuttle to Fuel Breast Cancer Cell Growth. Cell Metab. 2018 Dec 4;28(6):805-807. PMID: 30517893.
Benajiba L, …, Puissant A. Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML. Leukemia. 2018 Nov 2. doi: 10.1038/s41375-018-0291-x. PMID: 30390009.
Fenouille N, Bassil CF, …, Puissant A. Creatine kinase pathway is a vulnerability in EVI1-positive Acute Myeloid Leukemia. Nat Med. 2017 Mar;23(3):301-313. PMID:28191887.
Puissant A, Fenouille N, Alexe G, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226-42. PMID: 24525236.
Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23. PMID: 23430699.